JP2018528257A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528257A5
JP2018528257A5 JP2018521190A JP2018521190A JP2018528257A5 JP 2018528257 A5 JP2018528257 A5 JP 2018528257A5 JP 2018521190 A JP2018521190 A JP 2018521190A JP 2018521190 A JP2018521190 A JP 2018521190A JP 2018528257 A5 JP2018528257 A5 JP 2018528257A5
Authority
JP
Japan
Prior art keywords
seq
group
amino acid
terminus
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018521190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528257A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/041544 external-priority patent/WO2017011312A1/en
Publication of JP2018528257A publication Critical patent/JP2018528257A/ja
Publication of JP2018528257A5 publication Critical patent/JP2018528257A5/ja
Priority to JP2021137990A priority Critical patent/JP7378446B2/ja
Priority to JP2023123206A priority patent/JP2023153906A/ja
Priority to JP2025144586A priority patent/JP2025172117A/ja
Pending legal-status Critical Current

Links

JP2018521190A 2015-07-10 2016-07-08 疎水性薬剤の効能を改善するための配合物 Pending JP2018528257A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021137990A JP7378446B2 (ja) 2015-07-10 2021-08-26 疎水性薬剤の効能を改善するための配合物
JP2023123206A JP2023153906A (ja) 2015-07-10 2023-07-28 疎水性薬剤の効能を改善するための配合物
JP2025144586A JP2025172117A (ja) 2015-07-10 2025-09-01 疎水性薬剤の効能を改善するための配合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562190909P 2015-07-10 2015-07-10
US62/190,909 2015-07-10
PCT/US2016/041544 WO2017011312A1 (en) 2015-07-10 2016-07-08 Formulations for improving the efficacy of hydrophobic drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021137990A Division JP7378446B2 (ja) 2015-07-10 2021-08-26 疎水性薬剤の効能を改善するための配合物

Publications (2)

Publication Number Publication Date
JP2018528257A JP2018528257A (ja) 2018-09-27
JP2018528257A5 true JP2018528257A5 (enExample) 2019-08-15

Family

ID=57758158

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018521190A Pending JP2018528257A (ja) 2015-07-10 2016-07-08 疎水性薬剤の効能を改善するための配合物
JP2021137990A Active JP7378446B2 (ja) 2015-07-10 2021-08-26 疎水性薬剤の効能を改善するための配合物
JP2023123206A Pending JP2023153906A (ja) 2015-07-10 2023-07-28 疎水性薬剤の効能を改善するための配合物
JP2025144586A Pending JP2025172117A (ja) 2015-07-10 2025-09-01 疎水性薬剤の効能を改善するための配合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021137990A Active JP7378446B2 (ja) 2015-07-10 2021-08-26 疎水性薬剤の効能を改善するための配合物
JP2023123206A Pending JP2023153906A (ja) 2015-07-10 2023-07-28 疎水性薬剤の効能を改善するための配合物
JP2025144586A Pending JP2025172117A (ja) 2015-07-10 2025-09-01 疎水性薬剤の効能を改善するための配合物

Country Status (12)

Country Link
US (1) US10532105B2 (enExample)
EP (1) EP3319980B8 (enExample)
JP (4) JP2018528257A (enExample)
KR (1) KR20180027532A (enExample)
CN (1) CN108350036B (enExample)
AU (1) AU2016291597B2 (enExample)
CA (1) CA2991655A1 (enExample)
DK (1) DK3319980T3 (enExample)
EA (1) EA201890271A1 (enExample)
IL (1) IL256486B2 (enExample)
MX (1) MX384254B (enExample)
WO (1) WO2017011312A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3319980T3 (da) * 2015-07-10 2021-11-22 Peptinovo Biopharma Inc Formuleringer til forbedring af virkningen af hydrofobe lægemidler
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
CN114401736A (zh) * 2019-08-13 2022-04-26 佩蒂诺沃生物制药公司 用于治疗伴随癌症治疗发生的化学疗法诱导的周围神经病变的palm
WO2022035818A2 (en) * 2020-08-11 2022-02-17 Peptinovo Biopharma, Inc. Peptides and formulations for cancer treatment

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20040234588A1 (en) 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
AUPR798901A0 (en) 2001-09-28 2001-10-25 Medvet Science Pty. Ltd. Spheroidal hdl particles with a defined phospholipid composition
BR0310099A (pt) 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
KR101186210B1 (ko) 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
US8097283B2 (en) 2004-01-15 2012-01-17 Mount Sinai School Of Medicine Methods and compositions for imaging
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
US20080249123A1 (en) * 2007-04-05 2008-10-09 Wyeth Wortmannin-rapamycin conjugate and uses thereof
US20090110739A1 (en) 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
BRPI0818881A2 (pt) 2007-10-23 2015-05-05 Cleveland Clinic Foundation Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo
WO2009059450A1 (en) * 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
US20110020242A1 (en) 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
US8058069B2 (en) * 2008-04-15 2011-11-15 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
RU2011101536A (ru) * 2008-06-18 2012-07-27 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us) Усовершенствованные пептидные медиаторы оттока холестерина
CN102215844A (zh) * 2008-09-17 2011-10-12 恩多塞特公司 抗叶酸剂的叶酸受体结合轭合物
EP2393472B1 (en) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
EP2658993B1 (en) * 2010-12-31 2014-10-01 Alphacore Pharma LLC Detection of lcat activity
JP2014132832A (ja) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体
WO2013188763A1 (en) * 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
CN103393597B (zh) * 2013-07-02 2015-06-17 北京大学 疏水性肽修饰的注射用长循环脂质体给药系统
CN104558117B (zh) * 2013-10-25 2018-01-16 复旦大学 一种乙酰胆碱受体介导靶向的d构型多肽及其应用
US10220046B2 (en) 2014-07-14 2019-03-05 The Regents Of The University Of Michigan Compositions and methods for disease treatment using nanoparticle delivered compounds
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
DK3319980T3 (da) * 2015-07-10 2021-11-22 Peptinovo Biopharma Inc Formuleringer til forbedring af virkningen af hydrofobe lægemidler

Similar Documents

Publication Publication Date Title
CN107337728B (zh) 脂蛋白复合物及其制备和用途
ES2342258T3 (es) Peptidos administrados oralmente para mejorar la aterosclerosis.
JP2012518006A5 (enExample)
JP2018528257A5 (enExample)
EP2574623A3 (en) Peptide vaccines for cancers expressing tumor-associated antigens
JP2011507807A5 (enExample)
US20230302145A1 (en) Surfactant protein c mimics displaying pathogen- or allergen-binding moieties
US11434267B2 (en) Peptides having reduced toxicity that stimulate cholesterol efflux
KR101993937B1 (ko) 염증 억제용 펩티드
JP2011525181A (ja) コレステロール流出の改良型ペプチドメディエータ
US7153490B2 (en) Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors
JP6810690B2 (ja) 疾患組織に対する選択性を有するファルマコフォアを含む組成物およびその生成方法
US20050058697A1 (en) Cell penetrating therapeutic agents
CN110612097B (zh) 脂质体药物递送媒介物
WO2002066067A2 (en) Albumin-based drug delivery system and antimicrobial peptides
KR20180027532A (ko) 소수성 약물의 효능 개선용 제형
CA3127985A1 (en) Bi-specific extracellular matrix binding peptides and methods of use thereof
CN111164094B (zh) 抗癌肽及其用途
Chiangjong et al. Membrane Attacking Peptides: A New Involving Cancer Therapy
Dathe et al. 28 Cellular Uptake of Liposomal and Micellar Carriers Mediated by ApoE-Derived Peptides
JPWO2021030359A5 (enExample)
WO2012014046A2 (en) Supramolecular aggregates as drug carriers on cell expressing receptors for branched neurotensin